Published in J Clin Oncol on September 01, 2006
Early detection of colorectal cancer recurrence in patients undergoing surgery with curative intent: current status and challenges. J Cancer (2014) 1.16
The current landscape of locally advanced rectal cancer. Nat Rev Clin Oncol (2011) 0.99
A Low Lymphocyte-to-Monocyte Ratio Predicts Unfavorable Prognosis in Pathological T3N0 Rectal Cancer Patients Following Total Mesorectal Excision. J Cancer (2015) 0.90
Adjuvant radiotherapy following total mesorectal excision for stage IIA rectal cancer: is it beneficial? Int J Colorectal Dis (2010) 0.86
Elevated platelet count as predictor of recurrence in rectal cancer patients undergoing preoperative chemoradiotherapy followed by surgery. Int Surg (2015) 0.84
Total mesorectal excision for rectal cancer in an unselected population: quality assessment in a low volume center. Int J Colorectal Dis (2009) 0.83
Practicability of quality goals for the treatment of rectal cancer. Int J Colorectal Dis (2010) 0.81
Oncologic outcomes of primary and post-irradiated early stage rectal cancer: a retrospective cohort study. World J Gastroenterol (2011) 0.80
Selective use of preoperative chemoradiotherapy for T3 rectal cancer can be justified: analysis of local recurrence. World J Surg (2013) 0.80
In the era of total mesorectal excision: adjuvant radiotherapy may be unnecessary for pT3N0 rectal cancer. Radiat Oncol (2014) 0.80
Preoperative chemoradiotherapy for clinically diagnosed T3N0 rectal cancer. Surg Today (2015) 0.78
The outcomes of therapeutic decision in lower 3rd rectal cancer patients. Medicine (Baltimore) (2016) 0.77
Prognostic and Predictive Model for Stage II Colon Cancer Patients With Nonemergent Surgery: Who Should Receive Adjuvant Chemotherapy? Medicine (Baltimore) (2016) 0.77
Prognostic Effect of Pretreatment Serum Carcinoembryonic Antigen Level: A Useful Tool for Prediction of Distant Metastasis in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy and Total Mesorectal Excision. Medicine (Baltimore) (2015) 0.76
Predicting Individualized Postoperative Survival for Stage II/III Colon Cancer Using a Mobile Application Derived from the National Cancer Data Base. J Am Coll Surg (2015) 0.75
Prognostic factors in the patients with T2N0M0 colorectal cancer. World J Surg Oncol (2016) 0.75
Do all locally advanced rectal cancers require radiation? A review of literature in the modern era. J Gastrointest Oncol (2010) 0.75
A predictive nomogram improved diagnostic accuracy and interobserver agreement of perirectal lymph nodes metastases in rectal cancer. Oncotarget (2016) 0.75
Identification of locally advanced rectal cancer with low risk of local recurrence. PLoS One (2015) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 26.90
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res (2009) 24.11
International network of cancer genome projects. Nature (2010) 20.35
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol (2009) 8.68
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol (2005) 8.08
Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev (2009) 8.08
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol (2004) 7.16
Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2005) 4.10
Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group. J Clin Oncol (2008) 3.82
Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA (2005) 3.46
Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res (2006) 3.32
Genomic and biological characterization of exon 4 KRAS mutations in human cancer. Cancer Res (2010) 3.24
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother (2007) 3.16
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
"MIATA"-minimal information about T cell assays. Immunity (2009) 2.90
Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas. Ann Surg (2004) 2.84
Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev (2006) 2.74
Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J Clin Oncol (2012) 2.74
Hospital and surgeon procedure volume as predictors of outcome following rectal cancer resection. Ann Surg (2002) 2.71
Adequacy of 1-cm distal margin after restorative rectal cancer resection with sharp mesorectal excision and preoperative combined-modality therapy. Ann Surg Oncol (2003) 2.69
p63 expression profiles in human normal and tumor tissues. Clin Cancer Res (2002) 2.68
Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg (2004) 2.62
Rate of pathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum (2004) 2.52
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet (2009) 2.51
Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol (2009) 2.50
Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg (2002) 2.47
Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol (2013) 2.43
American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma. J Clin Oncol (2007) 2.41
Thymidylate synthase expression in hepatic tumors is a predictor of survival and progression in patients with resectable metastatic colorectal cancer. J Clin Oncol (2003) 2.36
Defining the critical hurdles in cancer immunotherapy. J Transl Med (2011) 2.32
Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery (2009) 2.29
Pathologic classification and clinical behavior of the spectrum of goblet cell carcinoid tumors of the appendix. Am J Surg Pathol (2008) 2.27
The value of splenic preservation with distal pancreatectomy. Arch Surg (2002) 2.27
Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg (2007) 2.22
Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg (2005) 2.19
The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys (2005) 2.18
Elective bowel resection for incurable stage IV colorectal cancer: prognostic variables for asymptomatic patients. J Am Coll Surg (2003) 2.16
Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome. Cancer Lett (2006) 2.12
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers. Proc Natl Acad Sci U S A (2009) 2.09
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. Cancer Immun (2010) 2.07
Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol (2008) 2.07
Have the changes in treatment of rectal cancer made a significant difference to our patients? Oncology (Williston Park) (2011) 2.06
Whole body 18FDG-PET and the response of esophageal cancer to induction therapy: results of a prospective trial. J Clin Oncol (2003) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res (2009) 1.98
Counting alleles to predict recurrence of early-stage colorectal cancers. Lancet (2002) 1.96
Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg (2009) 1.94
cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol (2008) 1.93
Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol (2005) 1.92
The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg (2006) 1.90
Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut (2013) 1.89
Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer (2002) 1.85
Harmonization of immune biomarker assays for clinical studies. Sci Transl Med (2011) 1.84
Accuracy of endorectal ultrasonography in preoperative staging of rectal tumors. Dis Colon Rectum (2002) 1.83
Adenocarcinoma of the duodenum: importance of accurate lymph node staging and similarity in outcome to gastric cancer. Ann Surg Oncol (2004) 1.82
L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition. Int J Cancer (2007) 1.76
Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol (2014) 1.76
Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol (2004) 1.74
Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg (2003) 1.74
Surgeon volume compared to hospital volume as a predictor of outcome following primary colon cancer resection. J Surg Oncol (2003) 1.73
Association of survival and disease progression with chromosomal instability: a genomic exploration of colorectal cancer. Proc Natl Acad Sci U S A (2009) 1.72
c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases. Cancer Lett (2008) 1.71
CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol (2008) 1.70
Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol (2005) 1.67
Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg (2002) 1.66
Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg (2002) 1.65
Heterotopic ossification in high-energy wartime extremity injuries: prevalence and risk factors. J Bone Joint Surg Am (2009) 1.65
Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg (2005) 1.64